Literature DB >> 28297158

Unclassifiable interstitial lung diseases: Clinical characteristics and survival.

Charlotte Hyldgaard1, Elisabeth Bendstrup1, Athol U Wells2, Ole Hilberg1.   

Abstract

BACKGROUND AND
OBJECTIVE: Unclassifiable disease in chronic interstitial lung disease (ILD) is a common and challenging problem but has been insufficiently studied. The 2013 update of the international multidisciplinary classification of the idiopathic interstitial pneumonias presented a classification based on observed disease behaviour with the purpose of providing guidance to clinicians in the management of these patients. The aim of this study was to apply the new disease behaviour classification (DBC) and the previously validated ILD-gender age physiology (GAP) score to a cohort of unclassifiable ILD patients and to assess the prognostic value of these two composite approaches.
METHODS: Unclassifiable ILD patients were identified from the population-based ILD registry at Aarhus University Hospital, Denmark, that includes all ILD patients diagnosed at the department from 2003 to 2009. The DBC was assessed retrospectively based on clinical presentation and diagnostic examinations at presentation and short-term follow-up.
RESULTS: Unclassifiable ILD was diagnosed in 24% of the cohort (105 of 431). Survival in unclassifiable ILD was intermediate between idiopathic pulmonary fibrosis (IPF) and non-IPF controls (idiopathic non-specific interstitial pneumonia (NSIP), hypersensitivity pneumonitis and connective tissue disease-associated ILD). The DBC and the ILD-GAP index were strong individual predictors of outcome in a dichotomized regression model (hazard ratio (HR): 6.3 (95% CI: 1.8-21.2) for the DBC and HR: 6.7 (95% CI: 2.2-20.0) for ILD-GAP). Both approaches remained significant in a common regression model (HR: 4.5 (95% CI: 1.3-15.7) for the DBC and HR: 5.1 (95% CI: 1.3-15.7) for ILD-GAP).
CONCLUSION: The DBC approach showed strong prognostic value in unclassifiable ILD. The DBC and the ILD-GAP were complementary predictors of outcome in unclassifiable ILD.
© 2016 Asian Pacific Society of Respirology.

Entities:  

Keywords:  diagnosis; interstitial lung disease; prognosis; survival; unclassifiable

Mesh:

Year:  2016        PMID: 28297158     DOI: 10.1111/resp.12931

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  13 in total

1.  A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective.

Authors:  Christopher J Ryerson; Tamera J Corte; Joyce S Lee; Luca Richeldi; Simon L F Walsh; Jeffrey L Myers; Jürgen Behr; Vincent Cottin; Sonye K Danoff; Kevin R Flaherty; David J Lederer; David A Lynch; Fernando J Martinez; Ganesh Raghu; William D Travis; Zarir Udwadia; Athol U Wells; Harold R Collard
Journal:  Am J Respir Crit Care Med       Date:  2017-11-15       Impact factor: 21.405

2.  Transbronchial Lung Cryobiopsy for Diagnosing Interstitial Lung Disease: A Retrospective Single-Center Experience.

Authors:  Jin Han Park; Ji Hoon Jang; Hyun Kuk Kim; Hang-Jea Jang; Sunggun Lee; Seong-Ho Kim; Ji Yeon Kim; Hee Eun Choi; Ji-Yeon Han; Da Som Kim; Min Kyun Kang; Eunsu Kang; Il Hwan Kim; Jae Ha Lee
Journal:  Tuberc Respir Dis (Seoul)       Date:  2022-08-02

3.  Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases.

Authors:  Francesco Bonella; Vincent Cottin; Claudia Valenzuela; Marlies Wijsenbeek; Florian Voss; Klaus B Rohr; Susanne Stowasser; Toby M Maher
Journal:  Adv Ther       Date:  2022-05-14       Impact factor: 4.070

4.  Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From a post-hoc Analysis.

Authors:  Maria Molina-Molina; Michael Kreuter; Vincent Cottin; Tamera J Corte; Frank Gilberg; Klaus-Uwe Kirchgaessler; Judit Axmann; Toby M Maher
Journal:  Front Med (Lausanne)       Date:  2022-06-17

5.  Using Bronchoscopic Lung Cryobiopsy and a Genomic Classifier in the Multidisciplinary Diagnosis of Diffuse Interstitial Lung Diseases.

Authors:  Fayez Kheir; Ala Alkhatib; Gerald J Berry; Philip Daroca; Lisa Diethelm; Reinaldo Rampolla; Shigeki Saito; David L Smith; David Weill; Marjorie Bateman; Ramsy Abdelghani; Joseph A Lasky
Journal:  Chest       Date:  2020-05-25       Impact factor: 9.410

6.  Acute exacerbation of unclassifiable idiopathic interstitial pneumonia: comparison with idiopathic pulmonary fibrosis.

Authors:  Noriyuki Enomoto; Hyogo Naoi; Yuya Aono; Mineo Katsumata; Yasuoki Horiike; Hideki Yasui; Masato Karayama; Hironao Hozumi; Yuzo Suzuki; Kazuki Furuhashi; Tomoyuki Fujisawa; Naoki Inui; Yutaro Nakamura; Takafumi Suda
Journal:  Ther Adv Respir Dis       Date:  2020 Jan-Dec       Impact factor: 4.031

7.  Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial.

Authors:  Toby M Maher; Tamera J Corte; Aryeh Fischer; Michael Kreuter; David J Lederer; Maria Molina-Molina; Judit Axmann; Klaus-Uwe Kirchgaessler; Vincent Cottin
Journal:  BMJ Open Respir Res       Date:  2018-09-04

8.  Nationwide cloud-based integrated database of idiopathic interstitial pneumonias for multidisciplinary discussion.

Authors:  Tomoyuki Fujisawa; Kazutaka Mori; Masashi Mikamo; Takashi Ohno; Kensuke Kataoka; Chikatoshi Sugimoto; Hideya Kitamura; Noriyuki Enomoto; Ryoko Egashira; Hiromitsu Sumikawa; Tae Iwasawa; Shoichiro Matsushita; Hiroaki Sugiura; Mikiko Hashisako; Tomonori Tanaka; Yasuhiro Terasaki; Shinobu Kunugi; Masashi Kitani; Ryo Okuda; Yasuoki Horiike; Yasunori Enomoto; Hideki Yasui; Hironao Hozumi; Yuzo Suzuki; Yutaro Nakamura; Junya Fukuoka; Takeshi Johkoh; Yasuhiro Kondoh; Takashi Ogura; Yoshikazu Inoue; Yoshinori Hasegawa; Naohiko Inase; Sakae Homma; Takafumi Suda
Journal:  Eur Respir J       Date:  2019-05-18       Impact factor: 16.671

9.  Baseline characteristics and comorbidities in the CAnadian REgistry for Pulmonary Fibrosis.

Authors:  J H Fisher; M Kolb; M Algamdi; J Morisset; K A Johannson; S Shapera; P Wilcox; T To; M Sadatsafavi; H Manganas; N Khalil; N Hambly; A J Halayko; A S Gershon; C D Fell; G Cox; C J Ryerson
Journal:  BMC Pulm Med       Date:  2019-11-27       Impact factor: 3.317

Review 10.  Progression in the Management of Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Diseases, Where Are We Now and Where We Would Like to Be.

Authors:  Tinne Goos; Laurens J De Sadeleer; Jonas Yserbyt; Geert M Verleden; Marie Vermant; Stijn E Verleden; Wim A Wuyts
Journal:  J Clin Med       Date:  2021-03-23       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.